MAR-ZOLMITRIPTAN TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ZOLMITRIPTAN

可用日期:

MARCAN PHARMACEUTICALS INC

ATC代码:

N02CC03

INN（国际名称）:

ZOLMITRIPTAN

剂量:

2.5MG

药物剂型:

TABLET

组成:

ZOLMITRIPTAN 2.5MG

给药途径:

ORAL

每包单位数:

250ML

处方类型:

Prescription

治疗领域:

SELECTIVE SEROTONIN AGONISTS

產品總結:

Active ingredient group (AIG) number: 0134381001; AHFS:

授权状态:

APPROVED

授权日期:

2013-01-11

产品特点

Page | 1
PRODUCT MONOGRAPH
PR
MAR-ZOLMITRIPTAN
ZOLMITRIPTAN TABLETS
2.5 MG
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Date of Revision:
July 20, 2020
K2E
1A2
Ottawa, O
ntario
2
Gurdwara Road, Suite 112
Marcan Pharmaceuticals Inc.
Submission
Control
No.:
240962
Page | 2
TABLE OF CONTENTS
PRODUCT MONOGRAPH
......................................................................................................
1
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
18
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 21
STORAGE AND STABILITY
............................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
............................